Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment

Table 3 In vitro effect of stimulation with atorvastatin (0.001–10 μM) on PBMC and CD4+

PBMC
		Atorvastatin (μM)
	Control	0.001	0.1	1	5	10
Resting cell viability (% of PI negative)^a	100 ± 2.11	101.41 ± 0.64	96.89 ± 3.63	102.82 ± 1.28	=	101.43 ± 2.19
PHA-induced cell viability^b	100.00 ± 27.59	106.10 ± 9.81	107.40 ± 14.65	107.50 ± 23.48	50.76 ± 42.44*	33.72 ± 20.61**
PHA-induced cell proliferation^b	100.00 ± 26.24	98.61 ± 15.79	96.83 ± 35.19	83.47 ± 25.37	62.26 ± 22.45	33.82 ± 22.84**
PHA-induced IL-4 mRNA expression^a	100.00 ± 38.99	=	=	103.90 ± 35.17	98.97 ± 40.82	83.34 ± 37.06
PHA-induced IFN-γ mRNA expression^a	100.00 ± 48.40	=	=	102.50 ± 32.99	56.97 ± 32.36	17.03 ± 10.88*
	CD4+
		Atorvastatin (μM)
	PHA (10 μg/ml)	0.001	0.1	1	5	10
Cell viability^a	100 ± 10.66	98.12 ± 2.92	103.60 ± 7.14	84.88 ± 20.64	53.04 ± 17.73*	34.69 ± 17.28**
Cell proliferation^b	100.30 ± 34.75	91.92 ± 13.94	105.10 ± 18.60	109.60 ± 42.90	37.38 ± 4.37*	13.03 ± 10.32**
IL-4 mRNA expression^a	100.00 ± 25.99	=	=	133.20 ± 64.78	98.97 ± 33.77	62.11 ± 6.19
IFN-γ mRNA expression^a	100.00 ± 39.62	=	=	127.20 ± 35.17	123.70 ± 66.18	54.17 ± 27.68

Cells were cultured for 1 (a) or 5 (b) days as appropriate. Values are expressed as percentage of resting values (presented in table as control) or of values obtained after stimulation with PHA (10 ng/ml) and finally expressed as mean ± SD of at least 4–6 separate experiments; P values were assessed by ANOVA followed by Dunnett comparison
* = P < 0.05; ** = and P < 0.0001 vs respective control

ISSN: 1471-2261